Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 8
1989 5
1990 5
1991 14
1992 16
1993 24
1994 30
1995 41
1996 45
1997 34
1998 34
1999 25
2000 34
2001 19
2002 20
2003 20
2004 24
2005 29
2006 17
2007 15
2008 20
2009 24
2010 26
2011 18
2012 17
2013 11
2014 4
2015 14
2016 7
2017 5
2018 10
2019 11
2020 6
2021 11
2022 2
2023 8
2024 10
2025 8
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

652 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.
Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Gu J, Pocock G, Papanicolaou GA. Chou S, et al. J Infect Dis. 2025 Mar 17;231(3):e470-e477. doi: 10.1093/infdis/jiae469. J Infect Dis. 2025. PMID: 39302855 Free PMC article. Clinical Trial.
One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir resistance in vitro. Viral clearance was confirmed in 17 (74%) of 23 patients with emergent maribavir resistance after retreatment with …
One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir …
Valganciclovir for symptomatic congenital cytomegalovirus disease.
Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Kimberlin DW, et al. N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599. N Engl J Med. 2015. PMID: 25738669 Free PMC article. Clinical Trial.
BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. ...
BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been s …
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Asberg A, et al. Am J Transplant. 2007 Sep;7(9):2106-13. doi: 10.1111/j.1600-6143.2007.01910.x. Epub 2007 Jul 19. Am J Transplant. 2007. PMID: 17640310 Free article. Clinical Trial.
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. ...A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 wa …
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. ...A total of 321 …
Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.
Hertz MI, Jordan C, Savik SK, Fox JM, Park S, Bolman RM 3rd, Dosland-Mullan BM. Hertz MI, et al. J Heart Lung Transplant. 1998 Sep;17(9):913-20. J Heart Lung Transplant. 1998. PMID: 9773865 Clinical Trial.
All subjects received twice-daily ganciclovir treatment for 2 weeks. Thereafter, subjects received either daily or 3-times-weekly ganciclovir dosing until 90 days after transplantation. ...CONCLUSIONS: We conclude that intravenous ganciclovir given 3 times we …
All subjects received twice-daily ganciclovir treatment for 2 weeks. Thereafter, subjects received either daily or 3-times-weekly …
[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].
Xuan L, Huang H, Xu LP, Fu YW, Chen F, Wang Y, Wang SQ, Dong L, Wu JY, Wu DP. Xuan L, et al. Zhonghua Xue Ye Xue Za Zhi. 2025 Dec 14;46(12):1121-1128. doi: 10.3760/cma.j.cn121090-20250626-00300. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486656 Free PMC article. Clinical Trial. Chinese.
Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis.
Wang X, Wang L, Wu N, Ma X, Xu J. Wang X, et al. Chin Med J (Engl). 2015 Jan 5;128(1):46-50. doi: 10.4103/0366-6999.147808. Chin Med J (Engl). 2015. PMID: 25563312 Free PMC article. Clinical Trial.
The aim was to explore the clinical efficacy of oral ganciclovir (GCV) in the prevention of recurrent HSK. METHODS: A multicenter, prospective, randomized, single-blind, and controlled clinical trial was conducted from April 2010 to June 2013. ...
The aim was to explore the clinical efficacy of oral ganciclovir (GCV) in the prevention of recurrent HSK. METHODS: A multicenter, pr …
Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up.
Nigro G, Buzzi M, Catenaro M, Coclite E, Muselli M. Nigro G, et al. Viruses. 2025 May 17;17(5):720. doi: 10.3390/v17050720. Viruses. 2025. PMID: 40431731 Free PMC article. Clinical Trial.
STUDY DESIGN: In the 1990s, we noted that intravenous ganciclovir did not cure some children with severe sequelae due to congenital cytomegalovirus (CMV) infection. ...Neurological outcomes were normal in three of the ten children treated with foscarnet, in two of the ten …
STUDY DESIGN: In the 1990s, we noted that intravenous ganciclovir did not cure some children with severe sequelae due to congenital c …
Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Jacobson MA, Wulfsohn M, Feinberg JE, Davis R, Power M, Owens S, Causey D, Heath-Chiozzi ME, Murphy RL, Cheung TW, et al. Jacobson MA, et al. AIDS. 1994 Apr;8(4):451-9. doi: 10.1097/00002030-199404000-00006. AIDS. 1994. PMID: 8011248 Clinical Trial.
OBJECTIVE: To document response to foscarnet salvage therapy in patients with cytomegalovirus (CMV) retinitis who are intolerant of or resistant to ganciclovir. METHODS: Patients with AIDS and CMV retinitis who had documented hematologic intolerance or resistance to gan …
OBJECTIVE: To document response to foscarnet salvage therapy in patients with cytomegalovirus (CMV) retinitis who are intolerant of or resis …
652 results